Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
Gunar GüntherLorenzo GuglielmettiYousra KherabiRaquel DuarteChristoph Langenull nullPublished in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2024)
In only about half of the countries participating in the survey, clinicians had access to all the BPaL(M) regimen drugs. A complete DST for the BPaL(M) medicines was possible in less than half of the countries, because of the low accessibility of DST for pretomanid. Equal access to new regimens is urgently needed in Europe and a rapid scale up of DST, especially for pretomanid, is important to prevent unnoticed spread of drug resistance.